We’re Teva, a leader in UK healthcare, supplying a wide range of medicines to the UK health service across many disease areas.
We’ve been around for over 80 years and we supply more packs of medicines to the National Health Service than anyone else.1
Today we specialise in both generic and branded medicines, improving the lives of patients, whether it is by fighting infections, controlling cholesterol, relieving the symptoms of asthma, or providing lifesaving injectable medicines and pain relief for cancer sufferers. Our medicines are used in hospitals, pharmacies and clinics.
We’re the UK arm of Teva Pharmaceutical Industries Ltd; that means we're part of one of the top 10 pharmaceutical companies in the world. With over a century of experience in pharmaceuticals, Teva is a big player on the world stage, which brings considerable benefits to us in the UK.
As well as providing hundreds of generic medicines which are supplied to the country’s thousands of pharmacies and dispensaries, we also supply medicines to treat multiple sclerosis, cancer, pain, Parkinson’s disease and respiratory disorders like asthma and chronic obstructive pulmonary disease (COPD).
Globally, Teva is the world's leading generic drug maker, with a range of more than 1,000 molecules, with a presence in around 60 countries.
Teva's specialty medicines business focuses on conditions affecting the central nervous system, respiratory, oncology, pain, and women's health, as well as biologics.
Teva currently employs approximately 42,000 people around the world and reached $19.7 billion in net revenues in 2015.
We're constantly developing new medicines that patients need – adding to our medicines range with generic and branded therapies. A whole range of people work together to bring a new medicine to market: it's a real collaborative approach, not just in the UK but with our colleagues from around the world.
It takes between eight and 10 years to launch a generic medicine. The early years are spent investigating patents and working on the formulation. As the timeline counts down, the activities focus around gaining the licence, designing the packaging and working with our supply chain to ensure the medicine becomes available for patients as soon as the patent protection has expired.
It can take 10-15 years to develop an innovative medicine. These medicines show distinct advantages, or enhanced new benefits for patients, to already existing therapies. Consequently, costs of development consistently rise and development time is continually increasing.
1 Data on file - Teva UK Limited
2 British Generics Manufacturers Association http://www.britishgenerics.co.uk/ accessed on 21.04.16